XaTek
XaTek Inc. is a Cleveland, Ohio-based biomedical company developing ClotChip, a portable point-of-care device that uses miniaturized dielectric spectroscopy to assess whole-blood coagulation from a finger-stick sample. It targets hemophilia, DOAC monitoring, trauma, and pre-surgical clinical markets, and is currently in clinical trials following its 2020 FDA Breakthrough Device Designation.
- Company typePrivate
- Founded2016
- HeadquartersCleveland, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What XaTek does
XaTek Inc. is a privately held, Cleveland, Ohio-based biomedical company founded in 2016 that develops ClotChip, a portable point-of-care medical device for assessing whole-blood coagulation. The device applies miniaturized dielectric spectroscopy — originally developed over eight years by an electrical engineering team at Case Western Reserve University — to single-drop whole-blood samples obtained via routine finger stick. ClotChip quantitatively measures blood impedance without requiring application-specific reagents and is agnostic to the underlying cause of a coagulation defect, enabling use across multiple clinical markets including congenital hemophilia, direct oral anticoagulant (DOAC) therapy monitoring, trauma-induced coagulopathy, and pre-surgical screening. The company received FDA Breakthrough Device Designation in March 2020 and remains in the clinical trials phase, with completed and ongoing studies across University Hospitals Cleveland (including Rainbow Babies & Children Hospital), the Cleveland VA, and Cleveland Clinic's Global Cardiovascular Innovations Center, as well as a DoD/U.S. Navy-funded ruggedization program for field trauma use.
XaTek operates a B2B enterprise sales motion targeting clinical care facilities, research centers, pharmaceutical companies, and device/diagnostic companies. The company is headquartered administratively in Hudson, Ohio, while maintaining laboratory operations at the Cleveland Clinic Global Cardiovascular Innovations Center. Leadership consists of President & CEO John Zak and a team described as experienced medical device market disrupters and inventors. The underlying revenue model is expected to be hardware sales of the ClotChip device to clinical institutions, with potential recurring revenue from consumables or service agreements, though the company is pre-commercial and no pricing, ARR, or revenue figures have been publicly disclosed. XaTek has raised at least $9.1 million in a disclosed funding round (July 2018) and operates with 1–10 employees, consistent with a clinical-stage medical device company preparing for regulatory clearance and commercial launch.
XaTek firmographics
Firmographics- Name
- XaTek
- Legal name
- XaTek Inc.
- Website
- https://clotchip.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- XaTek Inc. is a Cleveland, Ohio-based biomedical company developing ClotChip, a portable point-of-care device that uses miniaturized dielectric spectroscopy to assess whole-blood coagulation from a finger-stick sample. It targets hemophilia, DOAC monitoring, trauma, and pre-surgical clinical markets, and is currently in clinical trials following its 2020 FDA Breakthrough Device Designation.
- Ownership category
- akta.pro rank
XaTek industry classification
Industry- Product category
- Point-of-Care Blood Coagulation Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industries
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where XaTek is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
XaTek business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: ClotChip is a portable point-of-care medical device. Revenue model likely involves device sales to clinical facilities and healthcare providers, with potential recurring revenue from consumables or service agreements.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
XaTek product offering
Product offeringCore offering
XaTek Inc. develops and is commercializing ClotChip, a portable point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to evaluate whole-blood coagulation from a single finger-stick blood drop. The device delivers both quantitative and qualitative measurements of the hemostatic process without requiring application-specific reagents, and is intended for use in clinical care, trauma field assessment, anticoagulant therapy monitoring, hemophilia management, and pre-surgical screening. The company is pre-commercial with the device currently in clinical studies after receiving FDA Breakthrough Device Designation in March 2020.
Product overview
XaTek offers a single unified product: ClotChip, a portable point-of-care device for blood coagulation assessment. ClotChip leverages proprietary miniaturized dielectric spectroscopy technology to analyze whole-blood samples and provide rapid clinical evaluation of coagulation at the point of care, serving markets including congenital blood disorders, anticoagulant therapy monitoring, trauma care, and pre-surgical screening.
Differentiator
Problem solved
Functional benefit
Brands
- ClotChip: A portable, point-of-care device capable of providing both quantitative and qualitative measurements relevant to a patient's entire hemostatic process using miniaturized dielectric spectroscopy.
Products and services
- ClotChip ClotChip is a portable, point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to analyze single-drop whole-blood samples obtained from a routine finger stick. The device provides both quantitative and qualitative measurements relevant to a patient's entire hemostatic process, detecting both non-cellular (coagulation factors) and cellular (platelet) abnormalities without requiring application-specific reagents. It serves clinical care facilities, hemophilia treatment centers, anticoagulant therapy monitoring, trauma care, and pre-surgical screening use cases.
Quantifiable outcome
- Currently in clinical trials - N=100 pre-surgical screening study completed
- +3 more outcomes
Companies that use XaTek
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
XaTek technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
XaTek partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- U.S. Food and Drug Administration (FDA)coreFDA granted Breakthrough Device Designation to ClotChip in March 2020, providing expedited review pathway and regulatory recognition of the device's potential to provide more effective treatment or diagnosis of life-threatening diseases.
- U.S. Navy / Department of DefensecoreDepartment of Defense's Combat Readiness Medical Research Program, in cooperation with the U.S. Navy, funded the ruggedization of ClotChip for field use in trauma settings including ambulances and helicopters.
- Case Western Reserve UniversitycoreTechnology origin - Case Western Reserve University electrical engineering team developed dielectric spectroscopy technology over more than eight years. XaTek licensed/commercialized this technology.
- Cleveland Clinic - Global Cardiovascular Innovations CentercoreCollaborative research partnership for device development and testing. XaTek maintains laboratory facilities at this location.
- University Hospitals of ClevelandcoreMultiple clinical trials including hypercoagulability in COVID-19 infections study and hemophilia sensitivity studies (N=100). Active research partnership for clinical validation.
- U.S. Department of Veterans Affairs, ClevelandcoreClinical study on ClotChip correlation to peak-trough blood concentration in apixaban and rivaroxaban subjects (N=24 enrollment closed).
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
XaTek competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Sells Xprecia Stride and a broad hemostasis analyzer portfolio (BCS, CA-series). Comparable as an established POC and central-lab coagulation diagnostics incumbent that ClotChip would compete against for hospital and clinic placements.
- Roche Diagnostics: Operates CoaguChek, the dominant point-of-care INR/coagulation monitoring system, and a global leader in central-lab hemostasis diagnostics. Directly comparable because it serves the same anticoagulation monitoring use case that ClotChip targets, with broad global distribution and recurring reagent revenue.
- Abbott: i-STAT system is a widely deployed POC platform with a coagulation cartridge. Comparable because it occupies the same bedside, finger-stick/coag cartridge workflow that ClotChip targets, and benefits from Abbott's hospital sales infrastructure.
- Diagnostica Stago: Specialized hemostasis diagnostics company with STA analyzers and reagents for central labs. Comparable as a focused coagulation diagnostics competitor that defines the standard-of-care hemostasis assay that ClotChip is positioned as more accessible than.
- Haemonetics: Blood and plasma component management company with TEG thromboelastography platform for perioperative and trauma coagulation assessment. Comparable as a trauma/perioperative hemostasis diagnostics competitor and potential strategic acquirer for XaTek's trauma franchise.
- Werfen (Instrumentation Laboratory): Hemochron and ROTEM product lines cover POC and central-lab coagulation. Highly comparable as a specialized coagulation diagnostics incumbent with deep hospital relationships across both routine anticoagulation and trauma/perioperative testing.
Emerging players
- Entegrion: Development-stage company focused on novel hemostasis and trauma diagnostics, with prior U.S. Department of Defense backing. Comparable as an emerging POC coagulation player with a defense/trauma angle similar to XaTek's DOD partnership.
- Sienco: Developer of Sonoclot, a viscoelastic POC coagulation analyzer for surgical and trauma settings. Comparable as a smaller, focused POC coagulation diagnostics company serving overlapping perioperative and trauma markets with a different underlying technology.
Direct peers
- HemoSonics: Developer of Quantra, a point-of-care viscoelastic hemostasis analyzer for perioperative and trauma settings. Most direct comparable: a venture-backed POC coagulation diagnostics company targeting similar perioperative/trauma use cases with a different underlying technology.
Regional players
- Helena Laboratories: U.S.-based manufacturer of POC and specialty coagulation/hemostasis instruments. Comparable as a mid-sized specialty coagulation diagnostics competitor with overlapping POC product positioning, though typically serving U.S. clinical labs more than point-of-care ambulatory use.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
XaTek social profiles
Digital presenceXaTek compliance and trust
Trust signalCompliance1 record
XaTek financial estimates
Financial estimateRevenue estimate
Valuation estimate
XaTek leadership team
Management profileNumber of profiles
Profiles1 record
XaTek funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
XaTek M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about XaTek
What does XaTek do?
XaTek Inc. develops and is commercializing ClotChip, a portable point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to evaluate whole-blood coagulation from a single finger-stick blood drop. The device delivers both quantitative and qualitative measurements of the hemostatic process without requiring application-specific reagents, and is intended for use in clinical care, trauma field assessment, anticoagulant therapy monitoring, hemophilia management, and pre-surgical screening. The company is pre-commercial with the device currently in clinical studies after receiving FDA Breakthrough Device Designation in March 2020.
Is XaTek a public or private company?
XaTek is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was XaTek founded?
XaTek was founded in 2016. It employs 1 to 10 people.
Where is XaTek based?
XaTek is headquartered in Cleveland, United States, in the North America region.
How does XaTek make money?
One revenue line is on record: medical Device Sales.
Who are XaTek's main competitors?
Broad incumbents on record are Siemens Healthineers, Roche Diagnostics, Abbott, Diagnostica Stago, Haemonetics and Werfen (Instrumentation Laboratory). Emerging players are Entegrion and Sienco. HemoSonics is listed as a direct peer. Helena Laboratories is listed as a regional player.
Does XaTek have an API?
No public API is recorded for XaTek.
What industry is XaTek in?
XaTek's product category is Point-of-Care Blood Coagulation Diagnostics. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 334510 and its SIC code is 3841.